Therapeutic proteins : strategies to modulate their plasma half-lives / edited by Roland Kontermann.

Includes bibliographical references and index.

General information -- Half-life modulating strategies : an introduction -- Pharmacokinetics and half-life of protein therapeutics -- Half-life extension through chemical and post-translational modifications -- Half-life extension through PEGylation -- Half-life extension of therapeutic proteins via genetic fusion to recombinant PEG mimetics -- Half-life extension through O-glycosylation -- Polysialic acid and polysialylation to modulate antibody pharmacokinetics -- Half-life extension through HESylation -- Half-life modulation involving recycling by the neonatal Fc receptor -- The biology of the neonatal Fc receptor (FcRn) -- half-life extension by fusion to the Fc region -- Monomeric Fc fusion technology: an approach to create long-lasting clotting factors -- The diverse roles of FcRn: implications for antibody engineering -- Half-life extension by fusion to recombinant albumin -- AlbudAb technology platform: versatile albumin binding domains for the development of therapeutics with tunable half-lives -- Half-life extension by binding to albumin through an albumin binding domain -- Half-life extension by binding to albumin through small molecules -- Half-life extension with pharmaceutical formulations -- Half-life extension with pharmaceutical formulations: liposomes -- Half-life extension with pharmaceutical formulations: nanoparticles by the miniemulsion process.

Online resource; title from resource home page (ebrary, viewed on June 17, 2014).

For this ready reference, the internationally renowned authority in the field, Roland Kontermann, has assembled a team of outstanding contributors from industry and academia to convey the worldwide knowledge on modifying therapeutic proteins in order to optimize their pharmacological potential. The result is a comprehensive work covering all approaches and aspects of the topic in one handy volume, making this indispensable reading for companies and research institutions working on the development of biopharmaceuticals.